Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 5Healthy Participants 5Breast Neoplasms 5Prostatic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Venous Thromboembolism 2Solid Tumor, Adult 2Neoplasm Metastasis 2Healthy Volunteers 2Endometrial Neoplasms 2Colorectal Neoplasms 2Cardiovascular Diseases 2cMET-dysregulated Advanced Solid Tumors 1Venous Thrombosis 1TP53 Y220C Mutation 1Stroke 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rectal Neoplasms 1Pulmonary Embolism 1Prostatic Neoplasms, Castration-Resistant 1Precancerous Conditions 1Peripheral Nervous System Diseases 1Pain 1Ovarian Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Liver Cirrhosis 1Leiomyosarcoma 1

Interventions

Rosuvastatin Calcium 2technetium 99m HYNIC-duramycin 1eltrombopag 1darolutamide 1Magnetic Iron Oxide Nanoparticles 1Gelatin 1Decision Support Techniques 1Contrast Media 1Cell Death 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Healthy Volunteers × Rosuvastatin Calcium × Clear all
NCT04542382 2025-03-30

BCRPmarker

University of California, San Francisco

Phase 1 Completed
11 enrolled

Healthy Volunteers

NCT02671097 2016-09-08

Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate

Bayer

Phase 1 Completed
30 enrolled

Healthy Volunteers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡